Director Joshua E. Prime of Levi Strauss & Co. filed a Form 4 on November 6, 2026, disclosing the acquisition of 111 shares of Class A Common Stock via dividend equivalent rights on November 4, 2026.
Noor Shain, Chief Technology Officer of Silvia, Inc. (NASDAQ:SVIA), filed an amended statement of changes in beneficial ownership on November 6, 2026, correcting a July 8, 2026 original filing related to a tax-withholding transaction dated July 6, 2026.
Director Patrick Artemis filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of 72 dividend equivalent rights in Levi Strauss & Co. (NASDAQ:LEVI) on November 4, 2026.
Director Jenny J. Ming filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of dividend equivalent rights tied to Levi Strauss & Co. Class A and Class B Common Stock, with transactions dated November 4, 2026.
Noor Shain, Chief Technology Officer of Silvia, Inc. (NASDAQ:SVIA), filed an amended statement of changes in beneficial ownership on November 6, 2026, correcting a Form 4 originally filed on October 8, 2026, in connection with a tax withholding transaction tied to restricted stock unit …
An amended initial beneficial ownership statement for Noor Shain, Chief Technology Officer of Silvia, Inc. (NASDAQ:SVIA), was filed on November 6, 2026, correcting and supplementing disclosures originally made on April 7, 2026, in connection with the company's April 6, 2026 merger transaction.
Director David S. Marberger filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of 77 shares of Class A Common Stock of Levi Strauss & Co. (NYSE:LEVI) on November 4, 2026, in the form of dividend equivalent rights.
Director Jeffrey J Jones II filed a Form 4 with the SEC on November 6, 2026, disclosing the acquisition of 71 dividend equivalent rights in Levi Strauss & Co. Class A Common Stock on November 4, 2026.
Director John LaRocca filed a Form 3 Initial Statement of Beneficial Ownership with the SEC on November 6, 2026, disclosing his initial beneficial ownership of securities in Elite Pharmaceuticals Inc /NV/ following a triggering event dated October 28, 2026.
Robyn Tannenbaum, President of Sunrise Realty Trust, Inc., filed a Form 4 on November 6, 2026 reporting the acquisition of 45,913 shares of common stock on November 5, 2026 upon completion of a merger between Southern Realty Trust Inc. and a wholly owned subsidiary …